Breast Cancer: Chemotherapy

Department of Health and Social Care written question – answered at on 7 February 2023.

Alert me about debates like this

Photo of Tan Dhesi Tan Dhesi Shadow Minister (Transport)

To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 16 January 2023 to Question 119098, on Breast Cancer: Chemotherapy, when NICE will publish its decision on whether the guidance on tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer will be updated following the 2021 review.

Photo of Tan Dhesi Tan Dhesi Shadow Minister (Transport)

To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 16 January 2023 to Question 119098 on Breast Cancer: Chemotherapy, whether appropriate data has been collected to reduce uncertainties in the evidence base for recommended technologies for tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer.

Photo of Helen Whately Helen Whately Minister of State (Department of Health and Social Care)

Following a review of its diagnostics guidance on tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer [DG34], the National Institute for Health and Care Excellence (NICE) has confirmed that an update of its guidance on tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer [DG34] is in the very early stages of development.

Further information will be made available on NICE’s website as development of the updated guidance progresses.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.